Today, there are second (for example ceritinib) and third generation (for example lorlatinib) ALK inhibitors available for NSCLC, so if a patient with ALK-positive IMT fails to respond to crizotinib, or if there is progression under crizotinib, these drugs could be an option to overcome the underlying resistance mechanisms. This evidence concerns the gene ALK and non-small cell lung carcinoma.